OvaScience Inc (NASDAQ:OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, announced today that the AUGMENTSM fertility treatment will be introduced to patients at IVI Valencia, a clinic within the IVI Group of 38 in vitro fertilization (IVF) clinics spanning nine countries in Europe, North America, South America and Asia. The AUGMENT treatment is not available in the United States.

“We were pleased to hear from experts at other IVF clinics how the AUGMENT treatment has helped improve success rates in women with very poor prognoses, with an impressive number of ongoing pregnancies,” saidAntonio Pellicer, M.D., Ph.D., President of the IVI Group. “We look forward to exploring how the AUGMENT treatment can assist us in achieving more pregnancies for the thousands of women and couples who visit our extensive IVF clinic network each year.”

The IVI Group was founded in Spain as the first medical institution specializing entirely in human reproduction and has grown to become a globally preeminent IVF institution. As a pioneer in new fertility techniques and treatments, more than 100,000 babies have been born with the help of the IVI Group, which performs more than 23,000 IVF cycles annually.

“Our partnership with the IVI Group, the largest clinic network in reproductive medicine, is a major step forward in bringing our AUGMENT treatment to as many women as possible,” said Michelle Dipp, M.D., Ph.D., Chief Executive Officer of OvaScience. “Babies have now been born to women using our AUGMENT treatment at all of the IVF clinics that currently offer it. We eagerly await the births of more healthy babies this year.”

The IVI clinic in Valencia will be the first in the IVI Group to participate in the AUGMENT preceptorship program, which is designed to obtain patient experience and training before making it commercially available. The AUGMENT treatment was introduced using this approach in IVF clinics in other regions. The AUGMENT treatment will be studied versus standard IVF per approval of La Comisión Nacional de Reproducción Humana (CNRHA). (Original Source)

Shares of OvaScience Inc closed yesterday at $28.30. OVAS has a 1-year high of $55.69 and a 1-year low of $9.76. The stock’s 50-day moving average is $29.78 and its 200-day moving average is $35.72.

On the ratings front, OvaScience has been the subject of a number of recent research reports. In a report issued on July 7, Oppenheimer analyst Rohit Vanjani reiterated a Buy rating on OVAS, with a price target of $60, which implies an upside of 112.0% from current levels. Separately, on June 18, H.C. Wainwright’s Andrew Fein maintained a Buy rating on the stock and has a price target of $100.

According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Rohit Vanjani and Andrew Fein have a total average return of 38.8% and 25.9% respectively. Vanjani has a success rate of 74.1% and is ranked #18 out of 3727 analysts, while Fein has a success rate of 61.6% and is ranked #113.

The street is mostly Bullish on OVAS stock. Out of 5 analysts who cover the stock, 5 suggest a Buy rating . The 12-month average price target assigned to the stock is $70.50, which represents a potential upside of 149.1% from where the stock is currently trading.

OvaScience Inc is a life science company engaged in discovery, development, and commercialization of new fertility treatments. Its patented technology is based on egg precursor cells found in the outer layer of a woman’s own ovaries.